1.
|
A JemalR SiegelJ XuCancer statistics,
2010CA Cancer J Clin60277300201010.3322/caac.20073
|
2.
|
BW RobinsonRA LakeAdvances in malignant
mesotheliomaN Engl J
Med35315911603200510.1056/NEJMra05015216221782
|
3.
|
BWS RobinsonAW MuskRA LakeMalignant
mesotheliomaLancet366397408200510.1016/S0140-6736(05)67025-0
|
4.
|
S BonassiM NeriGenetic biomarkers in human
population studiesHandbook of Genomic MedicineHF WillardGS
GinsburgElsevier2008
|
5.
|
A TramontanoV ValenciaEducation and
research infrastructuresCancer Systems Biology, Bioinformatics and
MedicineA CesarioF
MarcusSpringer201110.1007/978-94-007-1567-7_6
|
6.
|
V GennaroD UgoliniP ViarengoIncidence of
pleural mesothelioma in Liguria Region, Italy (1996–2002)Eur J
Cancer41270927142005
|
7.
|
D UgoliniM NeriPA CanessaThe CREST
biorepository: a tool for molecular epidemiology and translational
studies on malignant mesothelioma, lung cancer, and other
respiratory tract diseasesCancer Epidemiol Biomarkers
Prev1730133019200810.1158/1055-9965.EPI-08-0524
|
8.
|
M YuilleGJ van OmmenC BréchotBiobanking
for EuropeBrief Bioinform91424200810.1093/bib/bbm050
|
9.
|
National Cancer Institute, National
Institute of Health, US Department of Health and Human Services:
National Cancer Institute. Best practices for biospecimen
resources. June 2007. http://biospecimens.cancer.gov/practices/
|
10.
|
ISBER (International Society for
Biological and Environmental Repositories)Best practices for
repositories: collection, storage, and retrieval of human
biological materials for researchCell Preserv
Technol3548200510.1089/cpt.2005.3.5
|
11.
|
NT HollandMT SmithB EskenaziM
BastakiBiological sample collection and processing for molecular
epidemiological studiesMutat
Res543217234200310.1016/S1383-5742(02)00090-X12787814
|
12.
|
NT HollandL PflegerE BergerA HoM
BastakiMolecular epidemiology biomarkers – sample collection and
processing considerationsToxicol Appl Pharmacol2062612682005
|
13.
|
OECD Best Practice Guidelines for
Biological Resource CentresOECD, 2007 http://www.oecd.org/document/36/0,3343,en_2649_37407_38777060_1_1_1_37407,00.html.
|
14.
|
Common Minimum Technical Standards
Protocols for Biological Resource Centres Dedicated to Cancer
Research: Workgroup Report 2. Caboux E, Plymoth A and Hainaut P
(eds.). IARC, 2007.
|
15.
|
Data Schema and Harmonization Platform for
Epidemiological Research Montreal Canada, 2011. http://www.datashaper.org/
|
16.
|
I FortierPR BurtonPJ RobsonQuality,
quantity and harmony: the DataSHaPER approach to integrating data
across bioclinical studiesInt J
Epidemiol3913831393201010.1093/ije/dyq139
|
17.
|
Istituto Centrale di Statistica:
Classificazione delle Professioni, 2001
|
18.
|
J BousquetJ AntoP SterkSystems Medicine
and integrated care to combat non-communicable diseaseGenome
Med343201110.1186/gm25921745417
|
19.
|
KM FossC SimaD UgolinimiR-1254 and
miR-574-5p: serum-based microRNA biomarkers for early-stage
non-small cell lung cancerJ Thorac
Oncol6482488201110.1097/JTO.0b013e318208c78521258252
|
20.
|
GV GeeDC KoestlerBC
ChristensenDownregulated microRNAs in the differential diagnosis of
malignant pleural mesotheliomaInt J
Cancer12728592869201010.1002/ijc.2528521351265
|
21.
|
GV GeeML StaniferBC ChristensenSV40
associated miRNAs are not detectable in mesotheliomasBr J
Cancer103885888201010.1038/sj.bjc.660584820717113
|
22.
|
F GemignaniM NeriF BottariRisk of
malignant pleural mesothelioma and polymorphisms in genes involved
in the genome stability and xenobiotics metabolismMutat
Res6717683200910.1016/j.mrfmmm.2009.09.00319751749
|
23.
|
M BettiM NeriD FerrantePooled analysis of
NAT2 genotypes as risk factors for asbestos-related malignant
mesotheliomaInt J Hyg Environ
Health212322329200910.1016/j.ijheh.2008.08.00118838334
|
24.
|
P MagistrelliM NeriP GranoneK-ras
mutations in circulating DNA from pancreatic and lung cancers:
bridging methodology for a common validation of the molecular
diagnosis
valuePancreas37101102200810.1097/MPA.0b013e31815e72bc18580451
|
25.
|
S LandiF GemignaniM NeriPolymorphisms of
glutathione-S-transferase M1 and manganese superoxide dismutase are
associated with the risk of malignant pleural mesotheliomaInt J
Cancer12027392743200710.1002/ijc.2259017290392
|
26.
|
A CristaudoR FoddisA VivaldiClinical
significance of serum mesothelin in patients with mesothelioma and
lung cancerClin Cancer
Res1350765081200710.1158/1078-0432.CCR-07-062917785560
|
27.
|
IARC: International Lung Cancer
Consortium. Lyon, France, 2011. http://ilcco.iarc.fr
|